Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 |
| gptkbp:collaborator |
gptkb:National_Institutes_of_Health
|
| gptkbp:developed_by |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:discovery_year |
gptkb:2010
|
| gptkbp:dosage_form |
varies by trial
|
| gptkbp:formulation |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
AR-558
|
| gptkbp:invention |
patented
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:market_position |
not approved for market
|
| gptkbp:mechanism_of_action |
inhibitor of the m TOR pathway
|
| gptkbp:related_to |
other m TOR inhibitors
|
| gptkbp:research_focus |
oncology
|
| gptkbp:research_institutes |
gptkb:Massachusetts_Institute_of_Technology
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:service_frequency |
daily
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash |
| gptkbp:status |
investigational
|
| gptkbp:structure |
gptkb:Atom
|
| gptkbp:target_audience |
patients with solid tumors
|
| gptkbp:targets |
gptkb:Oncology
|
| gptkbp:bfsParent |
gptkb:The_Siege_of_AR-558
|
| gptkbp:bfsLayer |
5
|